Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OMER Omeros

Post-Mkt 12-11 17:33:45 EST

10.59

-0.65

-5.78%

盘后10.67

+0.08+0.76%

17:32 EST

High11.42	Low10.35	Vol1.56M
Open11.09	D1 Closing11.24	Amplitude9.52%
Mkt Cap750.84M	Tradable Cap683.59M	Total Shares70.90M
T/O16.80M	T/O Rate2.42%	Tradable Shares64.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OMER","market":"US","secType":"STK","nameCN":"Omeros","latestPrice":10.59,"timestamp":1765486800000,"preClose":11.24,"halted":0,"volume":1564144,"hourTrading":{"tag":"盘后","latestPrice":10.67,"preClose":10.59,"latestTime":"17:32 EST","volume":20079,"amount":212697.810792,"timestamp":1765492335399},"delay":0,"floatShares":64550800,"shares":70900459,"eps":-2.009792,"marketStatus":"Post-Mkt","change":-0.65,"latestTime":"12-11 17:33:45 EST","open":11.09,"high":11.42,"low":10.3504,"amount":16800056.205840003,"amplitude":0.09516,"askPrice":10.68,"askSize":102,"bidPrice":10.61,"bidSize":253,"shortable":3,"etf":0,"ttmEps":-2.009792,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1254974400000,"exchange":"NASDAQ","adjPreClose":11.24,"preHourTrading":{"tag":"盘前","latestPrice":11.03,"preClose":11.24,"latestTime":"09:22 EST","volume":3802,"amount":42393.97288,"timestamp":1765462923920},"postHourTrading":{"tag":"盘后","latestPrice":10.67,"preClose":10.59,"latestTime":"17:32 EST","volume":20079,"amount":212697.810792,"timestamp":1765492335399},"volumeRatio":1.322409,"impliedVol":1.9906,"impliedVolPercentile":0.972},"requestUrl":"/m/hq/s/OMER/wiki","defaultTab":"wiki","newsList":[{"id":"2588708114","title":"Sector Update: Health Care Stocks Decline Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2588708114","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588708114?lang=en_us&edition=fundamental","pubTime":"2025-12-02 04:51","pubTimestamp":1764622264,"startTime":"0","endTime":"0","summary":"Health care stocks dropped late Monday afternoon with the NYSE Health Care Index decreasing 1.1% and the Health Care Select Sector SPDR Fund  falling 1.3%.The iShares Biotechnology ETF  dropped 2.1%.In corporate news, Omeros  closed the asset sale and licensing deal with Novo Nordisk  for Omeros' candidate drug zaltenibart. Novo shares fell 1.7%, and Omeros shed 0.8%.UnitedHealth  agreed to sell its South American business Banmedica to private equity firm Patria Investments for $1 billion, Reuters reported Sunday. UnitedHealth shares fell 1.4%.Merck  said its investigational therapy MK-2214 was granted fast-track designation by the US Food and Drug Administration for the treatment of Alzheimer's disease. Merck shares fell 2.6%.Bausch Health  shares jumped 11% after the company said its aesthetic business, Solta Medical, completed the acquisition of Wuhan Shibo Zhenmei Technology, its long-time distribution partner in China.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BKPKM429.USD","SGXZ81514606.USD","OMER","LU2211815571.USD","LU0353189680.USD","UNH","LU0234572021.USD","LU0122379950.USD","LU2552382058.USD","LU0149725797.USD","LU1718418525.SGD","SGXZ31699556.SGD","LU1989771016.USD","IE0002270589.USD","LU1791710400.SGD","LU1989772840.SGD","IE0004445239.USD","LU1267930573.SGD","LU0976567544.SGD","BK4154","IE00BJJMRY28.SGD","MRK","LABU","IE00BJT1NW94.SGD","BK4588","LU0058720904.USD","IE00B19Z8X17.USD","LU1917777945.USD","BK7104","IE00BWXC8680.SGD","LU0310799852.SGD","LU2468319806.SGD","XLV","XBI","LU2264538146.SGD","IE00B2B36J28.USD","LU1571399168.USD","IBB","LU2552382215.SGD","LU0354030438.USD","LU0689472784.USD","LU1074936037.SGD","LU0965509010.AUD","LU0094547139.USD","LU1699723380.USD","LU0949170772.SGD","LU1116320901.HKD","NVO.AU","BHC"],"gpt_icon":1},{"id":"2588505777","title":"Omeros Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2588505777","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588505777?lang=en_us&edition=fundamental","pubTime":"2025-12-02 02:30","pubTimestamp":1764613800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OMER/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 01, 2025 13:30 ET (18:30 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER"],"gpt_icon":0},{"id":"2588277515","title":"Omeros Corp - Approves $100 Mln Share Repurchase Program - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588277515","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588277515?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:36","pubTimestamp":1764599780,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70NF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2588778504","title":"Omeros Corporation Prepays $67.1 Million Senior Secured Term Loan, Terminates Credit Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2588778504","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588778504?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:30","pubTimestamp":1764595857,"startTime":"0","endTime":"0","summary":"Omeros Corporation has prepaid the entire $67.1 million principal amount outstanding under its senior secured term loan, including a pre-payment premium, accrued and unpaid interest, and related expenses. This prepayment has resulted in the termination of the senior secured credit agreement and the release of all associated liens and covenants, such as the $25.0 million minimum liquidity covenant. The company expects that remaining proceeds from its recent asset sale will be sufficient to repay the outstanding $17.1 million principal balance on its 2026 Convertible Notes and fund over 12 months of operations, including the anticipated U.S. launch of narsoplimab for transplant-associated thrombotic microangiopathy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL1yszGQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"2588542778","title":"Omeros Corporation Announces Closing of Asset Purchase and License Agreement With Novo Nordisk for Omeros’ Clinical-Stage Masp-3 Inhibitor Zaltenibart (Oms906)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588542778","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588542778?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:30","pubTimestamp":1764595801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA4X4K9C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"2588778573","title":"Press Release: Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588778573","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588778573?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:30","pubTimestamp":1764595800,"startTime":"0","endTime":"0","summary":"Omeros Corporation  today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart . Zaltenibart is a first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3 -- the most upstream and key activator of the alternative pathway of the complement system -- and has shown multiple potential advantages over other alternative pathway inhibitors in development or on the market. The transaction was completed pursuant to an asset purchase and license agreement that was announced on October 15, 2025.Omeros is eligible to receive upfront and near-term milestone payments up to $340.0 million, of which the upfront amount of $240.0 million was paid in cash at closing. In total, Omeros is eligible to receive up to $2.1 billion including potential development and commercial milestones, plus tiered royalties on net sales.MASP-3 is responsible for converting complement pro-factor D to its active form, fac","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4532","LU1093756168.USD","LU1093756325.SGD","OMER","LU0154236417.USD","NVO","BK4007","IE00BKVL7J92.USD","BK4599","IE00BZ1G4Q59.USD","SSI"],"gpt_icon":1},{"id":"2587765551","title":"Omeros Corporation (NASDAQ:OMER): When Will It Breakeven?","url":"https://stock-news.laohu8.com/highlight/detail?id=2587765551","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587765551?lang=en_us&edition=fundamental","pubTime":"2025-11-29 20:48","pubTimestamp":1764420534,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Omeros Corporation's...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/omeros-corporation-nasdaqomer-when-will-it-breakeven","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/omeros-corporation-nasdaqomer-when-will-it-breakeven","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QID","OMER","USJW.SI","MNQmain","BK4007",".IXIC","QLD","TQQQ","TSYW.SI","USAW.SI","SQQQ","NVIW.SI","PSQ","NQmain"],"gpt_icon":1},{"id":"2584922921","title":"Omeros Corporation Q3 EPS USD -0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2584922921","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584922921?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:41","pubTimestamp":1763574060,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Omeros Corporation Q3 net income USD -30.9 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 13-NOV-202521:05:05.043 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD1Dmj4M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2584284889","title":"OMER S.p.a. Buy Rating: Strong Financial Performance and Strategic Initiatives Drive Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2584284889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584284889?lang=en_us&edition=fundamental","pubTime":"2025-11-19 23:35","pubTimestamp":1763566517,"startTime":"0","endTime":"0","summary":"OMER S.p.a., the Industrials sector company, was revisited by a Wall Street analyst on November 17. Analyst Alessio Olmi from TP ICAP MIDCAP mainta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/omer-s-p-a-buy-rating-strong-financial-performance-and-strategic-initiatives-drive-growth-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/omer-s-p-a-buy-rating-strong-financial-performance-and-strategic-initiatives-drive-growth-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"gpt_icon":0},{"id":"2584603753","title":"Omeros Corporation’s Earnings Call Highlights Strategic Moves","url":"https://stock-news.laohu8.com/highlight/detail?id=2584603753","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584603753?lang=en_us&edition=fundamental","pubTime":"2025-11-18 08:06","pubTimestamp":1763424374,"startTime":"0","endTime":"0","summary":"Omeros Corporation (($OMER)) has held its Q3 earnings call. Read on for the main highlights of the call. Omeros Corporation’s recent earnings call ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/omeros-corporations-earnings-call-highlights-strategic-moves?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/omeros-corporations-earnings-call-highlights-strategic-moves?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"gpt_icon":0},{"id":"2583468160","title":"Omeros Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583468160","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583468160?lang=en_us&edition=fundamental","pubTime":"2025-11-15 04:50","pubTimestamp":1763153400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OMER/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 15:50 ET (20:50 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER"],"gpt_icon":0},{"id":"2583848507","title":"Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2583848507","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583848507?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:54","pubTimestamp":1763132040,"startTime":"0","endTime":"0","summary":"U.S. stocks were lower, with the Dow Jones index falling more than 500 points on Friday.Shares of Legence Corp  rose sharply during Friday's session after delivering mixed third-quarter results in its first earnings report since going public.The company posted revenue of $708.01 million, up 26.2% year-over-year and ahead of analyst expectations of $639.78 million. Gross margin eased to 20.9% from 21.1% a year earlier, while earnings missed forecasts, with an EPS loss of 2 cents compared with consensus estimates calling for a profit of 6 cents.Legence shares jumped 10.7% to $36.89 on Friday.Here are some other big stocks recording gains in today’s session.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/14/Section-Of-A-Financial-Newspaper-Titled-_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/14/Section-Of-A-Financial-Newspaper-Titled-_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/11/48865610/legence-cidara-therapeutics-avadel-pharmaceuticals-omeros-and-other-big-stocks-moving-higher-on-friday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/11/48865610/legence-cidara-therapeutics-avadel-pharmaceuticals-omeros-and-other-big-stocks-moving-higher-on-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["CDTX","BK4139","BK4129","LGN","BK4007","OMER"],"gpt_icon":0},{"id":"2583505887","title":"Omeros Corp:  Files for $150 Mln Common Stock Offering - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583505887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583505887?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:26","pubTimestamp":1763123206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ0O6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2583577264","title":"Omeros Corp : Files for Mixed Shelf Offering, Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583577264","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583577264?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:08","pubTimestamp":1763118511,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ0SL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2583097523","title":"Omeros Corporation Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583097523","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583097523?lang=en_us&edition=fundamental","pubTime":"2025-11-14 12:33","pubTimestamp":1763094829,"startTime":"0","endTime":"0","summary":"Omeros Corporation ( ($OMER) ) has released its Q3 earnings. Here is a breakdown of the information Omeros Corporation presented to its investors. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/omeros-corporation-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/omeros-corporation-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2583951216","title":"Biopharmaceutical firm Omeros Q3 net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2583951216","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583951216?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:29","pubTimestamp":1763069362,"startTime":"0","endTime":"0","summary":"Biopharmaceutical firm Omeros Q3 net loss narrowsOverviewOmeros Q3 net loss narrows to $30.9 mln from $32.2 mln in prior yearCompany entered into a $2.1 bln asset purchase agreement with Novo NordiskO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP19B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2583512132","title":"Omeros Q3 Adj. EPS $(0.34) Beats $(0.45) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512132","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512132?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:28","pubTimestamp":1763069314,"startTime":"0","endTime":"0","summary":"Omeros (NASDAQ:OMER) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.45) by 23.6 percent. This is a 46.88 percent increase over losses of $(0.64) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48851204/omeros-q3-adj-eps-0-34-beats-0-45-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Omeros Q3 Adj. EPS $(0.34) Beats $(0.45) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER"],"gpt_icon":0},{"id":"2583311512","title":"Omeros reports Q3 adjusted EPS (34c), consensus (48c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583311512","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583311512?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:17","pubTimestamp":1763068645,"startTime":"0","endTime":"0","summary":"“Our team delivered a series of accomplishments in the third quarter that I believe position Omeros (OMER) for a potentially transformative period ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/omeros-reports-q3-adjusted-eps-34c-consensus-48c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/omeros-reports-q3-adjusted-eps-34c-consensus-48c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"gpt_icon":0},{"id":"2583141935","title":"BRIEF-Omeros Corporation Q3 EPS USD -0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2583141935","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583141935?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:11","pubTimestamp":1763068305,"startTime":"0","endTime":"0","summary":"BRIEF-Omeros Corporation Q3 EPS USD -0.47\n\n\nNov 13 (Reuters) - Omeros Corporation Q3 net income USD -30.9 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX99EEA0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"2583514191","title":"Omeros reports Q3 net loss from discontinued operations of $9.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583514191","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583514191?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:11","pubTimestamp":1763068263,"startTime":"0","endTime":"0","summary":"Omeros Corporation reported a net loss from discontinued operations, net of tax, of $9.7 million, or $0.15 per share, for the third quarter of 2025, compared to net income from discontinued operations, net of tax, of $4.9 million, or $0.08 per share, in the same period of 2024. The decrease was mainly due to a non-cash remeasurement of the OMIDRIA contract royalty asset, reflecting changes in royalty estimates from Rayner. Interest expense was a credit of $13.4 million in the third quarter of 2025, compared to $4.1 million in the prior year quarter, primarily due to a non-cash remeasurement adjustment on the OMIDRIA royalty obligation to DRI. Interest and other income totaled $0.6 million, down from $2.3 million in the third quarter of 2024, mainly due to lower cash and investments available. Business developments during the quarter included completion of above-market financing in July, progress on the Novo Nordisk transaction expected to close before year-end, and anticipation of the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLWKPD3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.omeros.com","stockEarnings":[{"period":"1week","weight":0.0584},{"period":"1month","weight":0.703},{"period":"3month","weight":1.6762},{"period":"6month","weight":2.3059},{"period":"1year","weight":0.0664},{"period":"ytd","weight":0.1377}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.006425},{"month":2,"riseRate":0.5625,"avgChangeRate":0.058594},{"month":3,"riseRate":0.625,"avgChangeRate":0.097428},{"month":4,"riseRate":0.375,"avgChangeRate":-0.031657},{"month":5,"riseRate":0.375,"avgChangeRate":-0.032445},{"month":6,"riseRate":0.3125,"avgChangeRate":0.036171},{"month":7,"riseRate":0.4375,"avgChangeRate":0.065457},{"month":8,"riseRate":0.3125,"avgChangeRate":-0.029297},{"month":9,"riseRate":0.3125,"avgChangeRate":-0.001727},{"month":10,"riseRate":0.5,"avgChangeRate":-0.042054},{"month":11,"riseRate":0.647059,"avgChangeRate":0.236058},{"month":12,"riseRate":0.529412,"avgChangeRate":0.029677}],"exchange":"NASDAQ","name":"Omeros","nameEN":"Omeros"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Omeros(OMER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Omeros,OMER,Omeros股票,Omeros股票老虎,Omeros股票老虎国际,Omeros行情,Omeros股票行情,Omeros股价,Omeros股市,Omeros股票价格,Omeros股票交易,Omeros股票购买,Omeros股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Omeros(OMER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction